Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Processing and turnover of the Hedgehog protein in the endoplasmic reticulum.
Chen X, Tukachinsky H, Huang CH, Jao C, Chu YR, Tang HY, Mueller B, Schulman S, Rapoport TA, Salic A. Chen X, et al. Among authors: tukachinsky h. J Cell Biol. 2011 Mar 7;192(5):825-38. doi: 10.1083/jcb.201008090. Epub 2011 Feb 28. J Cell Biol. 2011. PMID: 21357747 Free PMC article.
A model for the generation and interconversion of ER morphologies.
Shemesh T, Klemm RW, Romano FB, Wang S, Vaughan J, Zhuang X, Tukachinsky H, Kozlov MM, Rapoport TA. Shemesh T, et al. Among authors: tukachinsky h. Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):E5243-51. doi: 10.1073/pnas.1419997111. Epub 2014 Nov 17. Proc Natl Acad Sci U S A. 2014. PMID: 25404289 Free PMC article.
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
Kasi PM, Lee JK, Pasquina LW, Decker B, Vanden Borre P, Pavlick DC, Allen JM, Parachoniak C, Quintanilha JCF, Graf RP, Schrock AB, Oxnard GR, Lovly CM, Tukachinsky H, Subbiah V. Kasi PM, et al. Among authors: tukachinsky h. Clin Cancer Res. 2024 Feb 16;30(4):836-848. doi: 10.1158/1078-0432.CCR-23-2693. Clin Cancer Res. 2024. PMID: 38060240 Free PMC article.
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J, Kalinava N, Doshi P, Pavlick DC, Albacker LA, Ebot EM, Tukachinsky H, Pratt J, Fusaro G, Oxnard GR, Green G, Fabrizio D, Baden J. He J, et al. Among authors: tukachinsky h. J Immunother Cancer. 2023 Nov 30;11(11):e007339. doi: 10.1136/jitc-2023-007339. J Immunother Cancer. 2023. PMID: 38035725 Free PMC article. Clinical Trial.
28 results